• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Elucidation of immunostimulatory mechanism of IMiDs and antibody-drugs for optimized myeloma treatment

Research Project

Project/Area Number 17K09963
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Hematology
Research InstitutionKansai Medical University

Principal Investigator

ITO Tomoki  関西医科大学, 医学部, 准教授 (70434826)

Project Period (FY) 2017-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
KeywordsIMiDs / type I IFNs / Th2 immune response / allergy / multiple myeloma / antibody drugs / dendritic cells / CCL17 / 樹状細胞 / エロツズマブ / カルフィルゾミブ / イキサゾミブ / 多発性骨髄腫 / IFN-alpha / IFN-a / Th2 / 内科 / 免疫学
Outline of Final Research Achievements

We demonstrated that lenalidomide could sustain and potentially enhance IFN-alpha production from plasmacytoid dendritic cells (DCs). In addition, IMiDs suppressed the Th1-inducing capacity of myeloid DCs, instead promoting a Th2 response. The lenalidomide-associated rashes might be a result of an allergic response driven by Th2-axis activation. Our findings suggest clinical efficacy and rashes as a side effect of IMiDs are inextricably linked through immunostimulation. Thus, IMiDs enhances the DC-mediated IFN-alpha response and Th2 immune response, contributing to immune activation. As multiple myeloma is characterized by immune dysfunction involved in prognosis, our findings unveiled a novel target of IMiDs. IMiDs have the DC-mediated immunostimulatory activities, leading to amplification of a positive immune axis able to eliminate MM cells.

Academic Significance and Societal Importance of the Research Achievements

免疫調節薬IMiDsという薬剤が、なぜ多発性骨髄腫に対し効くのか?その免疫学的解析を樹状細胞という免疫システムの司令官をターゲットとして解明し得たことが学術的意義と言える。また、この薬剤を使用した場合、有害事象の皮疹が出ると、実は潜在的に治療効果が高い可能性があることが示された。この結果は、実臨床で非常に有益な情報と考えられ社会的意義があると考える。

Report

(4 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • Research Products

    (11 results)

All 2020 2019 2018 2017 Other

All Journal Article (3 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 3 results,  Open Access: 3 results) Presentation (7 results) (of which Int'l Joint Research: 3 results) Remarks (1 results)

  • [Journal Article] Immunomodulatory Drugs and Plasmacytoid Dendritic Cells: Cooperation in Multiple Myeloma Treatment2020

    • Author(s)
      ③Ito T.
    • Journal Title

      Journal of Blood Transfusions and Diseases

      Volume: 3 Pages: 136-143

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Immunomodulatory drugs suppress Th1-inducing ability of dendritic cells but enhance Th2-mediated allergic responses.2020

    • Author(s)
      ②Vien P, Ito T et al.
    • Journal Title

      Blood ADV.

      Volume: In press

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells2019

    • Author(s)
      Kibata Kayo, Ito Tomoki, Inaba Muneo, Tanaka Akihiro, Iwata Ryoichi, Inagaki-Katashiba Noriko, Phan Vien, Satake Atsushi, Nomura Shosaku
    • Journal Title

      Jounal of Blood Medicine

      Volume: 10 Pages: 217-226

    • DOI

      10.2147/jbm.s206459

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Elotuzumab enhances the Th2-mediated immune response of dendritic cell induced by Immunomodulatory Drugs (IMiDs).2019

    • Author(s)
      Azuma Y
    • Organizer
      61th American Society of Hematology Annual Meeting and Exposition
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Elotuzumab has the ability to enhance dendritic cell-mediated Th2 cell response2019

    • Author(s)
      Azuma Y
    • Organizer
      第82回日本血液学会学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] Myeloma cells have the ability to suppress Th1-inducing capacity but enhance Th2-mediated response of dendritic cells by producing factors other than soluble SLAMF72019

    • Author(s)
      Azuma Y
    • Organizer
      第44回日本骨髄腫学術集会
    • Related Report
      2019 Annual Research Report
  • [Presentation] e: Myeloma cells have the ability to suppress Th1-inducing capacity but enhance Th2-mediated response of dendritic cells by producing factors other than soluble SLAMF72018

    • Author(s)
      Yoshiko Azuma
    • Organizer
      The 61th American Society of Hematology (ASH) Annual Meeting(国際学会)
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research
  • [Presentation] Short-term exposure to a high concentration of carfilzomib stimulates plasmacytoid dendritic cells2018

    • Author(s)
      Yuta Yamanaka
    • Organizer
      日本血液学会
    • Related Report
      2018 Research-status Report
  • [Presentation] Clinical troughconcentration of ixazomibdoes not suppressfunction of human dendritic cell subsets2018

    • Author(s)
      Yusuke Sawai
    • Organizer
      日本血液学会
    • Related Report
      2018 Research-status Report
  • [Presentation] Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells2017

    • Author(s)
      Tomoki Ito
    • Organizer
      The 60th American Society of Hematology (ASH) Annual Meeting
    • Related Report
      2017 Research-status Report
    • Int'l Joint Research
  • [Remarks] 関西医科大学内科学第一講座

    • URL

      http://imed1.kmu-ac.jp/index.html

    • Related Report
      2019 Annual Research Report

URL: 

Published: 2017-04-28   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi